(A and B) Changes in the levels of DNA methyltransferases (DNMTs) transcripts on treatment of RASF for 2 weeks with 20 mM L-methionine (A) or betaine (B).

Slides:

Advertisements

Similar presentations

B) a) Figure S4. Dynamic changes of DNA methylation in the SPDEF promoter during goblet cells differentiation of PBECs from patients with COPD. a) PBECs.

Advertisements

Immunohistochemical (IHC) staining for CD68/CD21 and CD3/CD20 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral.

Multivariable model of abatacept retention in biologic-naïve patients.

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

Patients included in linear extrapolation and observed/last observation carried forward analyses at week 48. Patients who were rescued or discontinued.

Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Subgroup analyses of association of gout with incident AF by clinical characteristics that are risk factors for AF. Point estimates indicate the HR of.

Changes in evaluation indicators from baseline to 12 weeks per visit.

Subgroup analyses of association of gout with incident AF by key demographic characteristics, race and gender. Subgroup analyses of association of gout.

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

p75NTR, TrkA and sortilin expression levels in patients with JIA

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

Mean values of CANDEN spine inflammation score and for vertebral body and posterior elements subscores, bars represent the SEM; as observed (n=49, 47,

Patient disposition through 48 weeks in RA-BEYOND

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.

Frequency of patients in flare at each time point over 3 months

Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

P75NTR and disease severity (A) in persistent oligoarticular (n=29), extended oligoarticular (n=16) and polyarticular (n=13) patients p75NTR mRNA expression.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Effect of collagen-induced arthritis (CIA) and 3,4-dichloropropionaniline (DCPA) on osteoclast bone interface density determined by ATPa3 (TCIRG) labelling,

The identification of leucocyte subset-specific type 1 interferon (IFN-1) modules. The identification of leucocyte subset-specific type 1 interferon (IFN-1)

Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. Box plot of HAQ-DI scores at baseline, week 96 and week.

XY plots with regression lines (red) showing the relationship between average (left panel) and peak (right panel) tissue stress at all bone sites for dual-energy.

(A) Reduction of circulating stromal cell-derived factor (SDF)-1 levels over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

IFN and neutrophil gene expression studies.

Changes in microRNA expression on treatment of RASF for 2 weeks with 20 mM L-methionine or betaine. Changes in microRNA expression on treatment of RASF.

Probability plots JSN score at baseline (A), 10 years (B) and progression (C) for the different age groups (darkest dots: group

Levels of participation in the Psoriatic Arthritis Impact of Disease (PsAID) development process. Levels of participation in the Psoriatic Arthritis Impact.

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.

IL-6-dependent changes in preclinical phase of arthritis in gp130F759.

Expression and Activity of Methylation-Associated Proteins In Vivo and In Vitro (AandB) The protein level of methylation-associated proteins (DNMT1, DNMT3a,

(A–D). (A–D). B-cell and Ig changes. Mean changes in total CD3-CD20+ B-cells (A) and immunoglobulin (Ig) subclasses levels (B-D) were measured over 24 weeks.

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

CD25+ proliferation and suppression are independent functional variables in type 1 diabetes. CD25+ proliferation and suppression are independent functional.

ACR20 response rates. ACR20 response rates. ACR20 response rates based on non-responder imputation (NRI) for the 120/Q4W, 90/Q2W and placebo groups over.

Joint damage progression evaluated as a comparison between abatacept plus MTX (grey bar) and placebo plus MTX groups (open bar). Joint damage progression.

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

ACR20/50/70 response rates at week 24 (TP1 per-protocol set).

The thickness of the subchondral bone plate for healthy subjects and patients with osteoarthritis (OA). The thickness of the subchondral bone plate for.

The effect of 3,4-dichloropropionaniline (DCPA) treatment on collagen-induced arthritis (CIA) at 40 days. The effect of 3,4-dichloropropionaniline (DCPA)

Frequency of methotrexate (MTX) doses at 24 months (plot) and summary of MTX doses across the MTX dosing categories (low, medium, high) based on data at.

Ultrasonographic characteristics and synovitis pattern of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis under tumour.

Subject disposition through week 156 of treatment

Patient disposition after 2 years of treatment.

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

Satisfaction with control of RA

Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to minimum observed white blood cell.

(A) NKG2A and (B) NKG2C expression on NK cells in subjects with AS and HCs. The upper figure represents % of NK positive cells; the lower figure represents.

Sera metabolite profiles of patients with RA discriminate rituximab responders and non-responders. Sera metabolite profiles of patients with RA discriminate.

(A) Mean NMR spectra of patient sera show differences in metabolite intensities between responders and non-responders before (a) and 6 months after (b)

Joint pain location and severity.

Comparison of brain temperature values in the basal ganglia and white matter according to the initial degree of encephalopathy and the presence of brain.

Forest plot of major bleeding: the measure of the effect of morphine versus nonmorphine on major bleeding in each study was plotted using OR and 95% CI.

Forest plot showing the results of the meta-analysis on the effect of strength exercise on M.quadriceps femoris in people with rheumatoid arthritis and.

Forest plot showing the results of the meta-analysis on the effect of aerobic exercise on measured on VO2max in people with rheumatoid arthritis, spondyloarthritis.

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

(A) One-carbon cycle and polyamine metabolism regulate DNA methylation

ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 50% or 70% improvement criteria) in patients with rheumatoid arthritis randomised.

NRDC and TNF-α increase in synovial fluid from patients with RA

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

Kaplan-Meier failure curves with development of RA stratified by depression exposure. Kaplan-Meier failure curves with development of RA stratified by.

Presentation transcript:

(A and B) Changes in the levels of DNA methyltransferases (DNMTs) transcripts on treatment of RASF for 2 weeks with 20 mM L-methionine (A) or betaine (B). (A and B) Changes in the levels of DNA methyltransferases (DNMTs) transcripts on treatment of RASF for 2 weeks with 20 mM L-methionine (A) or betaine (B). The L-methionine-treated cells showed a trend towards more DNMT3B mRNA. At opposite, on betaine (but not L-methionine), expressions of DNMT1 and DNMT3A mRNAs were reduced by 35% and 40%. (C and D) A significant association between increases in DNA methylation and changes in DNMT3A transcripts expression was observed after betaine (D), but not after L-methionine-treated treatment (C). Statistics: (A and B) Box-and-Whisker plots, Wilcoxon signed rank test between RASF before and after treatment with L-methionine or betaine, *confirmed by Kruskal-Wallis with Dunn's post hoc tests (overall: p<0.05 for A. and p<0.001 for (B), *separately confirmed in (B) regarding DNMT1 and DNMT3A, n=9); (C and D) linear regression lines with 95% CI, Spearman's rank correlation coefficients. DNMT, de novo methyltransferase; RASF, rheumatoid arthritis synovial fibroblasts. Niharika Gaur et al. RMD Open 2016;2:e000299 Copyright © BMJ Publishing Group & EULAR. All rights reserved.